3 ms·

This is really interesting. They certainly have a reputation for killing 454. What other companies have they done this with?

• refurb 12y ago
  I wouldn't say Roche "killed" 454. Illumina is absolutely dominating the sequencing market. I would say killing something that isn't profitable is a good business decision.
  • new299 12y ago
    You might not, I might not. But they do have somewhat of a reputation for not executing well on the 454 technology. It has been said that they failed to scale out what was a fundamentally sound platform. That they didn't really push on density to the increase device throughput as much as they could have. The truth maybe that the technology just has fundamental limitations. But I'd would say that's not objectively clear. The Illumina (Solexa) platform also had significant limitations, it took a lot of platform development to get it where it is today. In contrast Illumina have executed quite well, providing systematic improvements to the Solexa platform.
• sitkack 12y ago
  This what it felt like with Combimatrix http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=13315 http://www.evaluategroup.com/Universal/View.aspx?type=Story&... who are still around but had a pivot and change of leadership.